231 related articles for article (PubMed ID: 34487766)
21. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.
Jin C; Yu B; Zhang J; Wu H; Zhou X; Yao H; Liu F; Lu X; Cheng L; Jiang M; Wu N
BMC Infect Dis; 2021 Apr; 21(1):357. PubMed ID: 33863281
[TBL] [Abstract][Full Text] [Related]
22. Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study.
Abdoli A; Aalizadeh R; Aminianfar H; Kianmehr Z; Teimoori A; Azimi E; Emamipour N; Eghtedardoost M; Siavashi V; Jamshidi H; Hosseinpour M; Taqavian M; Jalili H
Rev Med Virol; 2022 May; 32(3):e2305. PubMed ID: 34699647
[TBL] [Abstract][Full Text] [Related]
23. Tergitol-15-S-9 inactivates SARS-CoV-2 and boosts immunoassay signals.
Berg MG; Israeli E; Quaco E; Cloherty GA; Hemken PM
Biotechniques; 2021 Jul; 71(1):370-375. PubMed ID: 34139879
[TBL] [Abstract][Full Text] [Related]
24. Effects of Three Types of Inactivation Agents on the Antibody Response and Immune Protection of Inactivated IHNV Vaccine in Rainbow Trout.
Tang L; Kang H; Duan K; Guo M; Lian G; Wu Y; Li Y; Gao S; Jiang Y; Yin J; Liu M
Viral Immunol; 2016 Sep; 29(7):430-5. PubMed ID: 27548006
[TBL] [Abstract][Full Text] [Related]
25. The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test.
Jagt HJ; Bekkers ML; van Bommel SA; van der Marel P; Schrier CC
Biologicals; 2010 Jan; 38(1):128-34. PubMed ID: 19716316
[TBL] [Abstract][Full Text] [Related]
26. Development of a Purified Viral Preparation for Studies of COVID-19 (SARS-CoV-2) Biology.
Chepurnov AA; Kazachinskaya EI; Kazachkova EA; Sharshov KA; Kononova YV; Shelemba AA; Alekseev AY; Gulyeva MA; Voevoda MI; Shestopalov AM
Bull Exp Biol Med; 2021 Nov; 172(1):49-52. PubMed ID: 34787781
[TBL] [Abstract][Full Text] [Related]
27. A promising inactivated whole-virion SARS-CoV-2 vaccine.
Isakova-Sivak I; Rudenko L
Lancet Infect Dis; 2021 Jan; 21(1):2-3. PubMed ID: 33069282
[No Abstract] [Full Text] [Related]
28. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies.
Kozlovskaya LI; Piniaeva AN; Ignatyev GM; Gordeychuk IV; Volok VP; Rogova YV; Shishova AA; Kovpak AA; Ivin YY; Antonova LP; Mefyod KM; Prokosheva LS; Sibirkina AS; Tarasova YY; Bayurova EO; Gancharova OS; Illarionova VV; Glukhov GS; Sokolova OS; Shaitan KV; Moysenovich AM; Gulyaev SA; Gulyaeva TV; Moroz AV; Gmyl LV; Ipatova EG; Kirpichnikov MP; Egorov AM; Siniugina AA; Ishmukhametov AA
Emerg Microbes Infect; 2021 Dec; 10(1):1790-1806. PubMed ID: 34427172
[TBL] [Abstract][Full Text] [Related]
29. Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines.
Grenga L; Gallais F; Pible O; Gaillard JC; Gouveia D; Batina H; Bazaline N; Ruat S; Culotta K; Miotello G; Debroas S; Roncato MA; Steinmetz G; Foissard C; Desplan A; Alpha-Bazin B; Almunia C; Gas F; Bellanger L; Armengaud J
Emerg Microbes Infect; 2020 Dec; 9(1):1712-1721. PubMed ID: 32619390
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
Tanriover MD; Doğanay HL; Akova M; Güner HR; Azap A; Akhan S; Köse Ş; Erdinç FŞ; Akalın EH; Tabak ÖF; Pullukçu H; Batum Ö; Şimşek Yavuz S; Turhan Ö; Yıldırmak MT; Köksal İ; Taşova Y; Korten V; Yılmaz G; Çelen MK; Altın S; Çelik İ; Bayındır Y; Karaoğlan İ; Yılmaz A; Özkul A; Gür H; Unal S;
Lancet; 2021 Jul; 398(10296):213-222. PubMed ID: 34246358
[TBL] [Abstract][Full Text] [Related]
31. pH inactivation of SARS-CoV-2 and SARS-CoV in virus spiked protein A eluates from a mAb purification process.
Limburg H; Schwerdtner M; Wilson E; Roth B; Cassart JP; Werner AD; Harbig A; Böttcher-Friebertshäuser E; Stokes A
Biologicals; 2024 May; 86():101753. PubMed ID: 38492418
[TBL] [Abstract][Full Text] [Related]
32. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
33. Collection and transportation of SARS-CoV-2 and influenza A virus diagnostic samples: Optimizing the usage of guanidine-based chaotropic salts for enhanced biosafety and viral genome preservation.
Komu JG; Jamsransuren D; Matsuda S; Ogawa H; Takeda Y
Biochem Biophys Res Commun; 2024 Jun; 715():149994. PubMed ID: 38692139
[TBL] [Abstract][Full Text] [Related]
34. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development.
Ita K
Arch Med Res; 2021 Jan; 52(1):15-24. PubMed ID: 32950264
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings.
Widera M; Westhaus S; Rabenau HF; Hoehl S; Bojkova D; Cinatl J; Ciesek S
Med Microbiol Immunol; 2021 Aug; 210(4):235-244. PubMed ID: 34196781
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Chakraborty S; Mallajosyula V; Tato CM; Tan GS; Wang TT
Adv Drug Deliv Rev; 2021 May; 172():314-338. PubMed ID: 33482248
[TBL] [Abstract][Full Text] [Related]
37. Perilla (Perilla frutescens) leaf extract inhibits SARS-CoV-2 via direct virus inactivation.
Tang WF; Tsai HP; Chang YH; Chang TY; Hsieh CF; Lin CY; Lin GH; Chen YL; Jheng JR; Liu PC; Yang CM; Chin YF; Chen CC; Kau JH; Hung YJ; Hsieh PS; Horng JT
Biomed J; 2021 Jun; 44(3):293-303. PubMed ID: 34119448
[TBL] [Abstract][Full Text] [Related]
38. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
39. Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development.
Francis Z; Incerti S; Zein SA; Lampe N; Guzman CA; Durante M
Radiat Res; 2021 Mar; 195(3):221-229. PubMed ID: 33411888
[TBL] [Abstract][Full Text] [Related]
40. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
Jeong H; Choi YM; Seo H; Kim BJ
Front Immunol; 2021; 12():637654. PubMed ID: 33732258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
